Dr. Steve Worland, President and CEO of eFFECTOR Therapeutics is a pioneer in the Genomics 3.0 category. eFFECTOR is putting to work the research on selective translation regulator inhibitors (STRIs) and the key ways that cancer cells change their behavior and also change the immune system.
Steve says, "There are two revolutions in cancer in the last 10 to 15 years-- targeted therapies and immunotherapies. And we think STRIs is a third way to compliment one or both of those. And really with the idea here is that you could control a cancer for a long period of time. It's very hard to completely eradicate every tumor and every cancer cell in your body.
"But if you can restore control, your immune system can control the cancer. Hopefully, patients can live for years knowing they have the disease but not having it debilitate their daily life."